Inspections, Compliance, Enforcement, and Criminal Investigations
Campbell County Memorial Hospital - 1/11/01
Department of Health and Human Services
|Public Health Service
Food and Drug Administration
7920 Elmbrook Drive
Dallas. TX 75247-4982
January 11, 2001
RETURN RECEIPT REQUESTED
James R. LaManna
Campbell County Memorial Hospital
501 S. Burma Avenue
P.O. Box 3011
Gillette, WY 82716
RE: Inspection ID – 1559030006
Dear James R. LaManna,
On 12/15/2000, a representative of the State of Wyoming, acting on behalf of the Food and Drug Administration (FDA) inspected your facility. This inspection revealed a serious regulatory problem involving the mammography at your facility.
The Mammography Quality Standards Act of 1992 requires your facility to meet specific standards. These requirements help protect the health of women by assuring that a facility can perform quality mammography. The inspection revealed the following level 1 finding at your facility:
Level 1: Mammograms were processed in processor 01, Kodak, RP X-OMAT M6B, 6AN, 6AW, room Dardroorn at site Campbell County Memorial Hospital, when in was out of limits on 8 days.
The specific problem noted above appeared on your MQSA Facility Inspection Report, which was issued to your facility at the close of the inspection.
Level 1 findings may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility. They represent a serious violation of the law which may result in FDA taking regulatory action without further notice to you. These actions include, but are not limited to:
- Placing your facility under a Directed Plan of Correction.
- Charging your facility for the cost of on-site monitoring.
- Assessing civil money penalties up to S10.000 for each failure to substantially comply with, or each day of failure to substantially comply with, the Standards.
- Suspension or revocation of your facility's FDA certificate, or obtaining a court injunction against further mammography
In addition your response should address the Level 2 finding that was listed on the inspection report provided to you at the close of the inspection. The inspection revealed the following Level 2 finding:
Level 2: Corrective actions for processor QC failures were not documented at least once for processor 01, Kodak, RP X-OMAT M6B, 6AN, 6AW, room Darkroom at site Campbell County Memorial Hospital
Level 2: The radiologic technologist did not meet the continuing education requirement of having completed a minimum of 15 CEUs in mammography in a 36 month period: (11.5 CEUs in 36 months)
It is necessary for you to act on this matter immediately. You are required to respond to this office in writing within fifteen (15) working days from receipt of this letter. Please address the following:
- The specific steps you have taken to correct all of the violations noted in this letter.
- Each step your facility is taking to prevent the recurrence of similar violations.
- Equipment settings (including technique factors), raw test data, and calculated final results, where appropriate.
- Sample records that demonstrate proper record keeping procedures, if the findings relate to quality control or other records (Note: Patient names or identification should be deleted from any copies submitted).
Please submit your response to:
Deborah M. McGee, Radiation Specialist
Food and Drug Administration
7920 Elmbrook Drive, Suite 102
Dallas, Texas 75247-4982
This letter pertains only to findings of your inspection and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA's requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838-7715) or through the Internet at http://www.fda/gov/.
If you have more specific questions about mammography facility requirements, or about the content of this letter, please feel free to contact Deborah M. McGee at (214) 655-8100 ext. 138.
Gary L. Pierce
Regional Food and Drug Director